Hemophilia A and B
Rare Diseases
1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
BioMarin PharmaceuticalNOVATO, CA
1 programATHN 11: Liver Transplantation Outcomes StudyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
BayerBefovacimab
BioMarin PharmaceuticalATHN 11: Liver Transplantation Outcomes Study
Clinical Trials (2)
Total enrollment: 110 patients across 2 trials
Multiple Escalating Dose Study of BAY1093884 in Adults With Hemophilia A or B With or Without Inhibitors
Start: Jul 2018Est. completion: Oct 201924 patients
Phase 2Terminated
ATHN 11: Liver Transplantation Outcomes Study
Start: Jun 2020Est. completion: Dec 202286 patients
N/ACompleted
Related Jobs in Rare Diseases
Regional Gene Therapy Liaison - East Coast
Krystal Biotech
4h ago
Regional Gene Therapy Liaison - East Coast
Krystal Biotech
4h ago
Director, Clinical Development Operations Program Lead
Stoke Therapeutics
Bedford, Massachusetts, United States
4h ago
$236K - $260K/yr
Manager, Gene Therapy Operations (GTO)
Genetix Biotherapeutics
16h ago
From $130K/yr
Manager, Gene Therapy Operations (GTO)
Genetix Biotherapeutics
Somerville, Massachusetts, United States
16h ago
Ultra-Rare Disease Territory Account Specialist – Denver, CO
Novartis
Field Sales (USA)
Yesterday
$132K - $246K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space